CREATE A MORE REPRESENTATIVE IN VITRO MODEL TO INCREASE RESEARCH AND DEVELOPMENT SUCCESS
Nortis’ versatile microfluidic technology enables researchers to engineer a wide range of three-dimensional tissue microenvironments.
MICROFLUIDIC CHIPS AND SUPPORTING PERFUSION PLATFORM
About the size of a credit card, Nortis' unique microfluidic chips can be used to grow tissue microenvironments by seeding cells into tubular voids within extracellular matrix gels. The chip design offers the flexibility to generate a variety of tissue architectures based on cell types and matrix materials selected.
Small, portable perfusion platforms house the disposable chips and supporting media and collection reservoirs. Three-shelved docking stations that reside in a standard tissue culture incubator increase experimental throughput and flexibility by enabling up to twelve independent experiments to be run at a time. Perfusion through both the tissue lumen and surrounding extralumenal space allow physico-chemical gradients to be created and perfusion fluids and cells to be collected for downstream analysis. Each docking station shelf can easily be removed and the small perfusion platform/chip assemblies accommodate easy transport between the cell culture incubator, laminar flow hood, and microscope stage.
PRECISE CONTROL OF FLUIDIC FLOW
A key element of Nortis' technology is the ability to subject the tissues to fluid flow directly through the vessel lumen, which enables:
- Creation of vasculature and other tubular tissues
- Delivery of test compounds via the perfusate
- Exposure to shear and flow forces that are present in the body
- Independent perfusion through the vessel and matrix compartments
The entire Nortis system fits inside a standard tissue culture incubator.
SIMULATE THE HUMAN TISSUE MICROENVIRONMENT
Nortis provides an efficient, affordable alternative to animal testing that can accelerate research and advance scientific exploration. By supporting fluid flow, 3D tissue culture, and robust analysis in one scalable, user-friendly platform, Nortis offers a flexible approach to drive human health research and drug development.
NORTIS INNOVATION MAKES IT EASY TO:
- Engineer a variety of 3D tissue microenvironments
- Expose engineered tissues to flow and shear force via fluidic perfusion
- Perform real-time visualization under variable conditions
- Research human disease without relying on interspecies extrapolation
Small, disposable chips and perfusion hardware enable creation of various human tissue microenvironments for relevant insight into the world's most challenging biological questions. These tools are designed to serve a variety of applications, including:
Engineer, perfuse, and observe living human microvasculature
Reproduce functional units of specific organs
Confocal microscopy of a microvessel grown from human endothelial cells in a Nortis chip. The cell boundaries are labeled in green, the nuclei in blue. The red label is associated with laminin, indicating that the cells are depositing a basement membrane around the vessel.
Dr. Benjamin (Beno) Freedman of University of Washington (c) 2016 National Kidney Foundation
Nortis is a biotech company with locations in Seattle and Woodinville, WA. Founded by former UW faculty and spun-out in 2012, Nortis has developed technologies for generating small segments of human tissues and organs in microfluidic chips for the in vitro study of human health and disease.
The technology represents an important alternative to lab animals in pharmaceutical drug development, where more predictive preclinical test models are urgently needed to increase clinical trial success. This advance will overcome a large barrier to developing therapeutic drugs and vaccines for diseases like cancer, diabetes, Alzheimer’s disease, infectious diseases, cardiovascular disease, and stroke.
Nortis launched its commercial product in August 2015.
Nortis' vision is to facilitate groundbreaking scientific discoveries and accelerate their impact on improving human health, safety, and quality of life.
Nortis is dedicated to developing a new generation of in vitro systems that advance the discovery of novel therapies and reduce the timeline and costs associated with their translation into the clinic.
Nortis Awarded $688K for NIH Phase II SBIR Fast Track Grant in Human Blood Brain Barrier Model– Seattle, WA — August 18, 2017 — Nortis today announced the awarding of a $688K National Institutes of Health (NIH) grant. The award will provide funding for the third year of a Small Business Innovation Research (SBIR) Fast-track grant under award number R44NS095585 from the National Institute of Neurological Disorders and Stroke (NINDS).
Nortis will be at 3D Tissue Models Summit 2017, Boston, MA– If you will be at 3D Tissue Models Summit, August 28th - 30st 2017, come listen to a presentation by Science Director, Dr. Henning Mann, to learn more about our Organ-on-Chip products and solutions. If you will be in the area, email Chris@nortisbio.com to set up a meeting.
Sigma Sponsored Webinar with Ed Kelly (UW) and Nortis on Nephrotoxicity–
3D Nephrotoxicity applications & Nortis' microfluidic organ-on-chip technology
August 2016– Come visit the Nortis booth at 3D Tissue Models Summit, August 29th - 31st 2016, and listen to a presentation by Senior Research Scientist, Dr. Henning Mann, to learn more about our commercial product.
- View News Archive
1616 Eastlake Ave E, Suite 270
Seattle, WA 98102, USA
17280 Woodinville-Redmond Rd NE/Suite B828
Woodinville, WA 98072, USA